Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

As of March 31, 2025, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $106.9 million. The Company believes that its current cash, cash ...

Let's consider two stocks that have lagged the market this year but still look like great long-term options: Amazon (NASDAQ: ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...